Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma.

Trial Profile

Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Rituximab (Primary) ; Cytarabine; Dexamethasone; Folinic acid; Methotrexate; Procarbazine; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2017 Status changed from suspended to discontinued.
    • 08 Dec 2015 Primary endpoint has been met. (Complete response rate at the end of study treatment), as per results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top